Replimune Group, Inc. (REPL)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation

Ask a question about Replimune Group, Inc. (REPL)

Company Performance

Current Price

as of Oct 16, 2024

$11.41

P/E Ratio

N/A

Market Cap

$779.55M

Description

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Metrics

Overview

HQWoburn, MA
SectorHealth Technology
IndustryBiotechnology
TickerREPL
Price$11.41+8.25%

Trading Information

Market Cap$779.55M
Float76.78%
Average Daily Volume (1m)881,349
Average Daily Volume (3m)689,402
EPS-$3.34

Company

RevenueN/A
Rev Growth (1yr)N/A
Net Income-$53.77M
Gross MarginN/A
EBITDA MarginN/A
EBITDA-$57.07M

EV$229.50M
EV/RevenueN/A
P/EN/A
P/SN/A
P/B1.83

Documents

Factset

Factset Business Description

Factset Street Account

Replimune Group reports Q2 EPS ($0.90) vs FactSet ($0.81) [9 est, ($0.87)-(0.61)] ($12.87, 0.00) (2023-11-07T13:04:16Z)

Replimune Group presents updated results from Phase 1/2 ARTACUS trial of RP1 monotherapy ($14.20, 0.00) (2023-11-03T23:37:56Z)

Replimune Group presents updated data on RP2 in Uveal Melanoma during plenary session at the 20th International Congress of the Society for Melanoma Research ($10.83, 0.00) (2023-11-08T14:12:12Z)